Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 181

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial

Ziada, Ali, Barqawi, Albaha, Glode, L. Michael, Varella‐Garcia, Marileila, Crighton, Frances, Majeski, Susan, Rosenblum, Mark, Kane, Madeleine, Chen, Lin, Crawford, E. David·2004·The Prostate

Abstract

Purpose: To investigate the efficacy and toxicity of the antibody to the HER‐2/neu receptor (trastuzumab, Herceptin®) in the treatment of advanced hormone‐refractory prostate cancer (HRPC). Materials and Methods: Eighteen patients with HRPC were recruited for this phase II trial in which they received trastuzumab for 12 weeks or until disease progression or unacceptable toxicity was documented. HER‐2 receptor overexpression was evaluated using immunohistochemistry (IHC) and dual‐color fluorescence in‐situ hybridization (FISH) assays. Results: Trastuzumab as a single agent demonstrated little efficacy in treating HRPC. Two patients demonstrated stable disease based on a decrease in PSA level to less than 50% of baseline. No patient demonstrated a regression of radiographic bony or soft tissue metastatic disease. The medication was well tolerated in 16 patients (89%), and 2 patients (11%) had to be hospitalized for cardiac complications. Conclusions: Trastuzumab (Herceptin®) as a single agent demonstrated poor efficacy in treating HRPC. Based on promising results in treating breast cancer with regimens using Herceptin® and cytotoxic agents, a similar combination approach might demonstrate better efficacy in treating HRPC. © 2004 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.20065

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 181

Metadata

Authors
Ziada, A., Barqawi, A., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., & Crawford, E. D.
Venue
The Prostate
Publisher
Wiley
Published
2004-03-05
Volume
60
Issue
4
Pages
332-337
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W2127373124
Cited by
181
References
2
FWCI
12.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. https://app.cochat.ai/papers/10.1002/pros.20065
The paper
Ziada, A., Barqawi, A., Glode, L. M., Varella‐Garcia, M., Crighton, F., Majeski, S., Rosenblum, M., Kane, M., Chen, L., & Crawford, E. D. (2004). The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. The Prostate. https://doi.org/10.1002/pros.20065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.